Palantir's Triple Threat: Burry's Bet, AI Rivalry, and a Vanishing War Premium

Palantir shares fell over 6% as Anthropic's AI launch, a Michael Burry short bet, and easing Middle East tensions pressured the stock, despite strong earnings.

Palantir Technologies Inc. shares tumbled more than 6% on Tuesday, a stark underperformance against a broader software sector that gained 2.6%. The sell-off was triggered by a confluence of three distinct pressures: a high-profile short thesis, a direct competitive threat, and a shift in geopolitical sentiment that stripped the stock of a key support.

The most immediate catalyst was news from AI startup Anthropic. The company unveiled "Managed Agents," a hosted service for complex, autonomous AI tasks. This announcement stoked investor fears that expensive, license-based enterprise software—Palantir's core offering—could be displaced by more efficient AI infrastructure. The concern gained credibility from prominent investor Michael Burry, who publicly disclosed a short position in Palantir. Burry pointed to Anthropic's explosive growth, noting its annualized revenue run rate had surged from $9 billion to $30 billion in just a few months. By contrast, Palantir took two decades to reach a $5 billion annual revenue milestone.

Data from financial platform Ramp appears to support the competitive narrative, suggesting Anthropic captured roughly 73% of all new enterprise AI spending in early 2026. Burry argues Anthropic's solutions are simpler and more cost-effective for businesses. For Palantir, the threat is particularly acute in its sensitive defense business. Anthropic's Claude model is currently the only one approved and optimized for certain classified workflows within Palantir's Maven Smart System, a central platform for intelligence analysis and military targeting with multi-billion dollar contracts. While the Pentagon has approved alternative models, switching would be a non-trivial, months-long process involving rebuilding prompts, agent chains, and evaluation pipelines, carrying significant execution risk.

Geopolitical developments compounded the selling pressure. Pre-market gains, sparked by an announced two-week ceasefire regarding attacks on Iran, evaporated as the de-escalation in the Middle East dampened expectations for defense spending. This erased the "war premium" that had recently supported Palantir's share price.

Further headwinds are building in Europe. In the UK, National Health Service (NHS) staff are reportedly boycotting Palantir's Federated Data Platform, implemented under a 2023 contract worth £330 million. The boycott stems from concerns over data privacy, ethics, and trust in a US company handling sensitive health data. British government officials are reportedly examining an exit clause that could become active next year. This controversy risks complicating contract renewals and new business in other European markets.

These challenges collide with a fundamental picture of extreme strength and extreme valuation. The company's latest quarterly results were robust, with Q4 2025 revenue soaring 70% year-over-year to $1.41 billion, marking a tenth consecutive quarter of accelerating growth. GAAP net income reached $609 million, and the trailing twelve-month free cash flow margin stood at an exceptional 50.7%.

Yet, the market prices in near-perfect execution. The stock trades at approximately 235 times trailing earnings and 112 times forward earnings, with a price-to-sales ratio around 80. This leaves little room for disappointment. The stock is down roughly 15% year-to-date, well below its November 2025 all-time high. Its notorious volatility was on full display; the stock moved more than 5% in a single direction 33 times last year.

CEO Alex Karp remains ambitious, targeting at least $3.14 billion in US commercial revenue for 2026, a 115% increase, with a long-term goal of $45 billion in total revenue by the early 2030s. Analyst opinions are deeply divided, however. While the consensus price target sits at $197.77, Benchmark recently initiated coverage with a "Hold" rating and a $150 target. The wide gap underscores the uncertainty over whether Palantir can justify its premium against rising competition and shifting macro winds.